Q1 Earnings Forecast for KYMR Issued By B. Riley

Kymera Therapeutics, Inc. (NASDAQ:KYMR) – Investment analysts at B. Riley issued their Q1 2025 earnings per share estimates for shares of Kymera Therapeutics in a report issued on Monday, March 3rd. B. Riley analyst K. Patel forecasts that the company will post earnings per share of ($0.94) for the quarter. The consensus estimate for Kymera Therapeutics’ current full-year earnings is ($2.79) per share. B. Riley also issued estimates for Kymera Therapeutics’ Q2 2025 earnings at ($1.02) EPS, Q3 2025 earnings at ($1.09) EPS and Q4 2025 earnings at ($1.09) EPS.

Kymera Therapeutics (NASDAQ:KYMR) last issued its quarterly earnings data on Thursday, February 27th. The company reported ($0.88) earnings per share for the quarter, missing the consensus estimate of ($0.76) by ($0.12). Kymera Therapeutics had a negative net margin of 191.26% and a negative return on equity of 24.96%. The company had revenue of $7.39 million for the quarter, compared to the consensus estimate of $14.81 million.

Several other equities analysts have also recently weighed in on KYMR. Morgan Stanley raised their price objective on Kymera Therapeutics from $45.00 to $49.00 and gave the company an “equal weight” rating in a research note on Wednesday, November 6th. UBS Group lowered their target price on Kymera Therapeutics from $80.00 to $74.00 and set a “buy” rating on the stock in a research note on Monday, November 4th. Leerink Partners reiterated an “outperform” rating and set a $60.00 target price on shares of Kymera Therapeutics in a research note on Friday, December 27th. Stephens reiterated an “overweight” rating and set a $60.00 target price on shares of Kymera Therapeutics in a research note on Tuesday, January 21st. Finally, HC Wainwright lifted their target price on Kymera Therapeutics from $54.00 to $60.00 and gave the stock a “buy” rating in a research note on Friday. Three investment analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Kymera Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $56.69.

Kymera Therapeutics Trading Down 3.8 %

Shares of NASDAQ:KYMR opened at $30.17 on Tuesday. The stock’s fifty day simple moving average is $38.81 and its two-hundred day simple moving average is $43.66. Kymera Therapeutics has a 1-year low of $29.16 and a 1-year high of $53.27. The stock has a market cap of $1.95 billion, a PE ratio of -12.89 and a beta of 2.18.

Insider Buying and Selling at Kymera Therapeutics

In other Kymera Therapeutics news, COO Jeremy G. Chadwick sold 1,383 shares of Kymera Therapeutics stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $30.45, for a total transaction of $42,112.35. Following the completion of the transaction, the chief operating officer now owns 67,800 shares of the company’s stock, valued at $2,064,510. The trade was a 2.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Ellen Chiniara sold 3,129 shares of the business’s stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $41.75, for a total value of $130,635.75. Following the transaction, the insider now directly owns 54,826 shares of the company’s stock, valued at $2,288,985.50. The trade was a 5.40 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 13,788 shares of company stock valued at $455,202 in the last quarter. 15.82% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of KYMR. Wellington Management Group LLP grew its holdings in shares of Kymera Therapeutics by 14.9% during the fourth quarter. Wellington Management Group LLP now owns 5,307,326 shares of the company’s stock worth $213,514,000 after purchasing an additional 688,967 shares in the last quarter. Avoro Capital Advisors LLC grew its holdings in shares of Kymera Therapeutics by 14.4% during the fourth quarter. Avoro Capital Advisors LLC now owns 5,150,000 shares of the company’s stock worth $207,184,000 after purchasing an additional 650,000 shares in the last quarter. Deerfield Management Company L.P. Series C purchased a new position in shares of Kymera Therapeutics during the fourth quarter worth about $23,856,000. Boxer Capital Management LLC purchased a new position in shares of Kymera Therapeutics during the fourth quarter worth about $17,098,000. Finally, Jennison Associates LLC boosted its stake in Kymera Therapeutics by 85.8% in the third quarter. Jennison Associates LLC now owns 797,681 shares of the company’s stock worth $37,754,000 after buying an additional 368,394 shares in the last quarter.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.